

Page 8, lines 6-13, replace by the following:

Influenza A matrix		
58-66	GILGFVFTL (SEQ ID NO: 5)	1
NY-ESO-1:		
155-163	QLSLLMWIT (SEQ ID NO: 3)	0.01
157-167	SLLMWITQCFL (SEQ ID NO: 1)	0.04
157-165	SLLMWITQC (SEQ ID NO: 2)	0.004
157-C165A	SLLMWITQA (SEQ ID NO: 6)	0.4
157-C165L	SLLMWITQL (SEQ ID NO: 7)	0.5
157-C165V	SLLMWITQV (SEQ ID NO: 8)	10

Page 18, lines 8-11: replace by the following:

The peptides may be combined with peptides that are other tumor rejection antigens to form “polytopes.” Exemplary peptides include those listed in U.S. Patent Application Serial Numbers 08/672,351, 08/718,964, now U.S. Patent No. 5,932,694, 08/487,135 now U.S. Patent No. 5,821,122, 08/530,569 and 08/880,963, all of which are incorporated by reference.

IN THE CLAIMS

Claims 1-48. (Canceled)

Claim 49. (New) A method for providing proliferation of cytolytic T cells subject, comprising contacting a cytolytic T cell precursor with a peptide of formula
SLLMWITQX (SEQ ID NO: 10),

wherein X is Ala, Val, Leu, Ile, Pro, Phe, Met, Trp, or Gly in an amount sufficient to bind to HLA molecules presented on cell surfaces and to provoke proliferation of cytolytic T cells.

Claim 50. (New) The method of claim 49, wherein X is Ala.

- Claim 51. (New) The method of claim 49, wherein X is Val.
- Claim 52. (New) The method of claim 49, wherein X is Leu.
- Claim 53. (New) The method of claim 49, wherein X is Ile, Pro, Phe, Met, Trp, or Gly.
- Claim 54. (New) The method of claim 49, comprising administering said peptide in a composition comprising an adjuvant.
- Claim 55. (New) A method for provoking proliferation of cytolytic T cells, comprising contacting a sample containing a cell capable of recombination with an isolated nucleic acid molecule which encodes the peptide of SEQ ID NO: 10, wherein said cell expresses said peptide and expresses it in a complex with an HLA molecule on its surface, and contacting cells presenting said complexes to a cytolytic T cell precursor, to provoke proliferation of cytolytic T cells.
- Claim 56. (New) The method of claim 55, wherein said isolated nucleic acid molecule is presented in an expression vector.